Effects of the adenosine A2A antagonist istradefylline on cognitive performance in rats with a 6-OHDA lesion in prefrontal cortex

The Rat Brain in Stereotaxic Coordinates

Paxinos, G., & Watson, C. (1983) · Elsevier eBooks · doi:10.1016/c2009-0-63235-9 · Cited by 28,585 · see citing works

The rat brain in stereotaxic coordinates (2nd edn)

Herman, J. P., & Watson, S. J. (1987) · Trends in Neurosciences · doi:10.1016/0166-2236(87)90017-8 · Cited by 1,751 · see citing works

Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment

Chaudhuri, К. R., & Schapira, A. H. V. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70068-7 · Cited by 1,739 · see citing works

A systematic review of prevalence studies of dementia in Parkinson's disease

Aarsland, D., ZACCAI, J. H., & Brayne, C. (2005) · Movement Disorders · doi:10.1002/mds.20527 · Cited by 1,689 · see citing works

Cognitive Deficit Caused by Regional Depletion of Dopamine in Prefrontal Cortex of Rhesus Monkey

Brozoski, T. J., Brown, R. M., Rosvold, H. E., & Goldman, P. S. (1979) · Science · doi:10.1126/science.112679 · Cited by 1,500 · see citing works

What contributes to quality of life in patients with Parkinson's disease?

Schrag, A. E. (2000) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.69.3.308 · Cited by 1,380 · see citing works

Cognitive deficits in Parkinson’s disease

Dubois, B., & Pillon, B. (1996) · Journal of Neurology · doi:10.1007/pl00007725 · Cited by 911 · see citing works

Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease

Kehagia, A. A., Barker, R. A., & Robbins, T. W. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70212-x · Cited by 883 · see citing works

Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease

Scatton, B., Javoy-Agid, F., Rouquier, L., Dubois, B., & Agid, Y. (1983) · Brain Research · doi:10.1016/0006-8993(83)90993-9 · Cited by 727 · see citing works

Tissue distribution of adenosine receptor mRNAs in the rat

Dixon, A. K., Gubitz, A. K., SIRINATHSINGHJI, D. J. S., Richardson, P. J., & Freeman, T. C. (1996) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1996.tb15561.x · Cited by 566 · see citing works

Mesocortical dopamine modulation of executive functions: beyond working memory

Floresco, S. B., & Magyar, O. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0404-5 · Cited by 426 · see citing works

Cognitive correlates of cortical cholinergic denervation in Parkinson’s disease and parkinsonian dementia

Bohnen, N. I., Kaufer, D. I., Hendrickson, R., Ivanco, L. S., Lopresti, B. J., Constantine, G. M., Mathis, C. A., Davis, J. G., Moore, R. Y., & DeKosky, S. T. (2006) · Journal of Neurology · doi:10.1007/s00415-005-0971-0 · Cited by 364 · see citing works

Perspectives on object-recognition memory following hippocampal damage: lessons from studies in rats

Mumby, D. G. (2001) · Behavioural Brain Research · doi:10.1016/s0166-4328(01)00367-9 · Cited by 356 · see citing works

Cognitive Impairment and the Brain Dopaminergic System in Parkinson Disease

Rinne, J. O., Portin, R. I., Ruottinen, H., Nurmi, E., Bergman, J. R., Haaparanta‐Solin, M., & Solin, O. H. (2000) · Archives of Neurology · doi:10.1001/archneur.57.4.470 · Cited by 337 · see citing works

A new one-trial test for neurobiological studies of memory in rats. III. Spatial vs. non-spatial working memory

Ennaceur, A., & Meliani, K. (1992) · Behavioural Brain Research · doi:10.1016/s0166-4328(05)80315-8 · Cited by 276 · see citing works

Cognitive impairment and dementia in Parkinson's disease

Pagonabarraga, J., & Kulisevsky, J. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.03.029 · Cited by 257 · see citing works

Combined Use of the Adenosine A2A Antagonist KW-6002 with l-DOPA or with Selective D1 or D2 Dopamine Agonists Increases Antiparkinsonian Activity but Not Dyskinesia in MPTP-Treated Monkeys

Kanda, T., Jackson, M. J., Smith, L. A., Pearce, R. K. B., Nakamura, J., Kase, H., Kuwana, Y., & Jenner, P. G. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7350 · Cited by 248 · see citing works

Caffeine reverses age-related deficits in olfactory discrimination and social recognition memory in rats

Prediger, R. D., Batista, L. C., & Takahashi, R. N. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.08.012 · Cited by 240 · see citing works

Increase of Extracellular Dopamine in Primate Prefrontal Cortex During a Working Memory Task

Watanabe, M., Kodama, T., & Hikosaka, K. (1997) · Journal of Neurophysiology · doi:10.1152/jn.1997.78.5.2795 · Cited by 236 · see citing works

Actions of adenosine A 2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP

Shiozaki, S., Ichikawa, S., Nakamura, J., Kitamura, S., Yamada, K., & Kuwana, Y. (1999) · Psychopharmacology · doi:10.1007/s002130051146 · Cited by 216 · see citing works

Adenosine, adenosine A2A antagonists, and Parkinson's disease

Jenner, P. G., Mori, A., Hauser, R. A., Morelli, M., Fredholm, B. B., & Chen, J. (2009) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2008.12.006 · Cited by 199 · see citing works

Clinical efficacy of istradefylline (KW‐6002) in Parkinson's disease: A randomized, controlled study

Mizuno, Y., Hasegawa, K., Kondo, T., Kuno, S., Yamamoto, M., & The Japanese Istradefylline Study Group (2010) · Movement Disorders · doi:10.1002/mds.23107 · Cited by 188 · see citing works

Differential Effects of Caffeine on Dopamine and Acetylcholine Transmission in Brain Areas of Drug-naive and Caffeine-pretreated Rats

Acquas, E. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00290-7 · Cited by 186 · see citing works

Enhanced role of adenosine A2A receptors in the modulation of LTP in the rat hippocampus upon ageing

Costenla, A. R., Diógenes, M., Canas, P., Rodrigues, R., Nogueira, C., Marôco, J., Agostinho, P., Ribeiro, J., Cunha, R. A., & de Mendonça, A. (2011) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2011.07719.x · Cited by 186 · see citing works

Adenosine receptor antagonists for cognitive dysfunction: a review of animal studies

Takahashi, R. N. (2007) · Frontiers in bioscience · doi:10.2741/2870 · Cited by 173 · see citing works

Cellular and behavioural effects of the adenosine A2a receptor antagonist KW‐6002 in a rat model of l ‐DOPA‐induced dyskinesia

Lundblad, M., Vaudano, E., & Cenci, M. A. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01632.x · Cited by 169 · see citing works

Istradefylline, a novel adenosine A 2A receptor antagonist, for the treatment of Parkinson’s disease

Jenner, P. G. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.6.729 · Cited by 160 · see citing works

Normal and abnormal functions of adenosine receptors in the central nervous system revealed by genetic knockout studies

Wei, C. J., Li, W., & Chen, J. (2010) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2010.12.018 · Cited by 151 · see citing works

Systemic administration of adenosine A2A receptor antagonist reverses increased GABA release in the globus pallidus of unilateral 6-hydroxydopamine-lesioned rats: a microdialysis study

Ochi, M., Koga, K., Kurokawa, M., Kase, H., Nakamura, J., & Kuwana, Y. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00250-5 · Cited by 128 · see citing works

Modulation of GABAergic transmission in the striatopallidal system by adenosine A 2A receptors

Mori, A., & Shindou, T. (2003) · Neurology · doi:10.1212/01.wnl.0000095211.71092.a0 · Cited by 121 · see citing works

Object recognition impairment in Fmr1 knockout mice is reversed by amphetamine: involvement of dopamine in the medial prefrontal cortex

Ventura, R., Pascucci, T., Catania, M. V., Musumeci, S. A., & Puglisi‐Allegra, S. (2004) · Behavioural Pharmacology · doi:10.1097/00008877-200409000-00018 · Cited by 121 · see citing works

Adenosine A2A receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats

Koga, K., Kurokawa, M., Ochi, M., Nakamura, J., & Kuwana, Y. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00745-7 · Cited by 118 · see citing works

Working memory deficits in transgenic rats overexpressing human adenosine A2A receptors in the brain

Giménez‐Llort, L., Schiffmann, S. N., Shmidt, T., Canela, L., Camón, L., Wassholm, M., Canals, M., Terasmaa, A., Fernández‐Teruel, A., Tobeña, A., et al. (2006) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2006.05.004 · Cited by 113 · see citing works

The effect of striatal dopamine depletion and the adenosine A2A antagonist KW-6002 on reversal learning in rats

O’Neill, M. J., & Brown, V. J. (2007) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2007.03.003 · Cited by 99 · see citing works

Attention and executive function deficits in chronic low‐dose MPTP‐treated non‐human primates

Decamp, E., & Schneider, J. S. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03586.x · Cited by 99 · see citing works

Blockade of adenosine A2A receptors reverses short-term social memory impairments in spontaneously hypertensive rats

Prediger, R. D., Fernandes, D., & Takahashi, R. N. (2004) · Behavioural Brain Research · doi:10.1016/j.bbr.2004.10.017 · Cited by 99 · see citing works

Adenosine and memory storage

Kopf, S. R., Melani, A., Pedata, F., & Pepeu, G. (1999) · Psychopharmacology · doi:10.1007/s002130051109 · Cited by 98 · see citing works

Age-related spatial working memory impairment is caused by prefrontal cortical dopaminergic dysfunction in rats

Mizoguchi, K., Shoji, H., Tanaka, Y., Maruyama, W., & Tabira, T. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2009.05.023 · Cited by 93 · see citing works

The effect of the selective reversible acetylcholinesterase inhibitor E2020 on extracellular acetylcholine and biogenic amine levels in rat cortex

Giacobini, E., Zhu, X., Williams, E., & Sherman, K. (1996) · Neuropharmacology · doi:10.1016/0028-3908(95)00157-3 · Cited by 89 · see citing works

Effects of Cholinesterase Inhibitors in Parkinson's Disease Dementia: A Review of Clinical Data

van Laar, T., Deyn, P. P. D., Aarsland, D., Barone, P., & Galvin, J. E. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00166.x · Cited by 83 · see citing works

Cholinesterase inhibitor effects on neurotransmitters in rat cortex in vivo.

Cuadra, G. R., Summers, K. L., & Giacobini, E. (1994) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22338-2 · Cited by 83 · see citing works

Spatial delayed alternation of rats in a T-maze: effects of neurotoxic lesions of the medial prefrontal cortex and of T-maze rotations

Sánchez-Santed, F., de Bruin, J. P. C., Heinsbroek, R. P. W., & Verwer, R. W. H. (1997) · Behavioural Brain Research · doi:10.1016/s0166-4328(97)83327-x · Cited by 80 · see citing works

Improved spatial recognition memory in mice lacking adenosine A2A receptors

Wang, J. H., Yuan, Y., & van den Buuse, M. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.01.005 · Cited by 78 · see citing works

Changes in cerebral neurotransmitters and metabolites induced by acute donepezil and memantine administrations: A microdialysis study

Shearman, E., Rossi, S., Szász, B. K., Jurányi, Z., Fallon, S. M., Pomara, N., Sershen, H. W., & Lajtha, Á. (2005) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2005.12.001 · Cited by 77 · see citing works

Preferential enhancement of working memory in mice lacking adenosine A2A receptors

Zhou, S., Zhu, M.-E., Shu, D., Du, X.-P., Song, X., Wang, X.-T., Zheng, R., Cai, X., Chen, J., & He, J. (2009) · Brain Research · doi:10.1016/j.brainres.2009.09.082 · Cited by 76 · see citing works

Pharmacological Characterization of a Novel, Potent Adenosine A1 and A2A Receptor Dual Antagonist, 5-[5-Amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1 H)-one (ASP5854), in Models of Parkinson’s Disease and Cognition

Mihara, T., Mihara, K., Yarimizu, J., Mitani, Y., Matsuda, R., Yamamoto, H., Aoki, S., Akahane, A., Iwashita, A., & Matsuoka, N. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.121962 · Cited by 76 · see citing works

Modulation of short-term social memory in rats by adenosine A1 and A2A receptors

Prediger, R. D., & Takahashi, R. N. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.11.049 · Cited by 74 · see citing works

Evaluation of distribution of adenosine A2A receptors in normal human brain measured with [11C]TMSX PET

Mishina, M., Ishiwata, K., Kimura, Y., Naganawa, M., Oda, K., Kobayashi, S., Katayama, Y., & Ishii, K. (2007) · Synapse · doi:10.1002/syn.20423 · Cited by 70 · see citing works

Antagonistic interaction between adenosine A2A and dopamine D2 receptors modulates the social recognition memory in reserpine-treated rats

Prediger, R. D., Cunha, C. D., & Takahashi, R. N. (2005) · Behavioural Pharmacology · doi:10.1097/01.fbp.0000166825.62130.9a · Cited by 59 · see citing works

Activation of adenosine receptors in the posterior cingulate cortex impairs memory retrieval in the rat

Pereira, G. S., Rossato, J. I., Sarkis, J. J. F., Cammarota, M., Bonan, C. D., & Izquierdo, I. (2005) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2004.12.002 · Cited by 59 · see citing works

Comparative studies of huperzine A, donepezil, and rivastigmine on brain acetylcholine, dopamine, norepinephrine, and 5-hydroxytryptamine levels in freely-moving rats

Liang, Y., & Tang, X.-C. (2006) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2006.00411.x · Cited by 55 · see citing works

Attentional Set-Shifting Deficit in Parkinson’s Disease Is Associated with Prefrontal Dysfunction: An FDG-PET Study

Sawada, Y., Nishio, Y., Suzuki, K., Hirayama, K., Takeda, A., Hosokai, Y., Ishioka, T., Itoyama, Y., Takahashi, S., Fukuda, H., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038498 · Cited by 50 · see citing works

Effects of rat medial prefrontal cortex temporal inactivation on a delayed alternation task

Izaki, Y., Maruki, K., Hori, K., & Nomura, M. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)02366-7 · Cited by 46 · see citing works

Worsening of Motor Function and Mood in a Patient With Parkinson's Disease After Pharmacologic Challenge With Oral Rivastigmine

Richard, I. H., Justus, A. W., Greig, N. H., Marshall, F. J., & Kurlan, R. (2002) · Clinical Neuropharmacology · doi:10.1097/00002826-200211000-00002 · Cited by 40 · see citing works

Desipramine attenuates working memory impairments induced by partial loss of catecholamines in the rat medial prefrontal cortex

Clinton, S. M., Sucharski, I. L., & Finlay, J. M. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0221-2 · Cited by 37 · see citing works

Purine modulation of dizocilpine effects on spontaneous alternation

Fraser, C. M., Fisher, A., Cooke, M. J., Thompson, I. D., & Stone, T. W. (1997) · Psychopharmacology · doi:10.1007/s002130050248 · Cited by 30 · see citing works

Distribution of adenosine A2A receptor antagonist KW-6002 and its effect on gene expression in the rat brain

Aoyama, S., Koga, K., Mori, A., Miyaji, H., Sekine, S., Kase, H., Uchimura, T., Kobayashi, H., & Kuwana, Y. (2002) · Brain Research · doi:10.1016/s0006-8993(02)03277-8 · Cited by 28 · see citing works

Characteristic of Cognitive Decline in Parkinson's Disease: A 1-Year Follow-Up

McKinlay, A., & Grace, R. C. (2011) · Applied Neuropsychology · doi:10.1080/09084282.2011.595453 · Cited by 7 · see citing works

How does adenosine control neuronal dysfunction and neurodegeneration?

Cunha, R. A. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13724 · Cited by 442 · see citing works

Adenosine A1 and A2A Receptors in the Brain: Current Research and Their Role in Neurodegeneration

Stockwell, J., Jakova, E., & Cayabyab, F. (2017) · Molecules · doi:10.3390/molecules22040676 · Cited by 206 · see citing works

The medial prefrontal cortex - hippocampus circuit that integrates information of object, place and time to construct episodic memory in rodents: Behavioral, anatomical and neurochemical properties

Chao, O. Y., de Souza Silva, M. A., Yang, Y.-M., & Huston, J. P. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.04.007 · Cited by 158 · see citing works

Optogenetic activation of intracellular adenosine A2A receptor signaling in the hippocampus is sufficient to trigger CREB phosphorylation and impair memory

Li, P., Rial, D., Canas, P. M., Yoo, J.-H., Li, W., Zhou, X., Wang, Y., van Westen, G. J. P., Payen, M.-P., Augusto, E., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.182 · Cited by 139 · see citing works

Adenosine Receptor Control of Cognition in Normal and Disease

Chen, J. (2014) · International review of neurobiology · doi:10.1016/b978-0-12-801022-8.00012-x · Cited by 137 · see citing works

Impact of Coffee and Cacao Purine Metabolites on Neuroplasticity and Neurodegenerative Disease

Camandola, S., Plick, N., & Mattson, M. (2018) · Neurochemical Research · doi:10.1007/s11064-018-2492-0 · Cited by 89 · see citing works

Inactivation of adenosine A2A receptors reverses working memory deficits at early stages of Huntington's disease models

Li, W., Silva, H. B. L., Real, J. I., Wang, Y., Rial, D., Li, P., Payen, M.-P., Zhou, Y., Müller, C. E., Tomé, Â. R., et al. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.03.030 · Cited by 91 · see citing works

An Overview of Adenosine A2A Receptor Antagonists in Parkinson's Disease

Jenner, P. G. (2014) · International review of neurobiology · doi:10.1016/b978-0-12-801022-8.00003-9 · Cited by 89 · see citing works

Purinergic Receptors of the Central Nervous System: Biology, PET Ligands, and Their Applications

Zarrinmayeh, H., & Territo, P. (2020) · Molecular Imaging · doi:10.1177/1536012120927609 · Cited by 63 · see citing works

The Pharmacological Potential of Adenosine A2A Receptor Antagonists for Treating Parkinson’s Disease

Mori, A., Chen, J., Uchida, S., Durlach, C., King, S. M., & Jenner, P. G. (2022) · Molecules · doi:10.3390/molecules27072366 · Cited by 66 · see citing works

Istradefylline improves daytime sleepiness in patients with Parkinson's disease: An open-label, 3-month study

Suzuki, K., Miyamoto, M., Miyamoto, T., Uchiyama, T., Watanabe, Y., Suzuki, S., Kadowaki, T., Fujita, H., Matsubara, T., Sakuramoto, H., et al. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2017.07.045 · Cited by 62 · see citing works

Aberrant adenosine A2A receptor signaling contributes to neurodegeneration and cognitive impairments in a mouse model of synucleinopathy

Hu, Q., Ren, X., Liu, Y., Li, Z., Zhang, L., Chen, X., He, C., & Chen, J. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.05.040 · Cited by 55 · see citing works

An evaluation of istradefylline treatment on Parkinsonian motor and cognitive deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque models

Ko, W. K. D., Camus, S. M. J., Li, Q., Yang, J., McGuire, S., Pioli, E. Y., & Bézard, E. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.07.012 · Cited by 53 · see citing works

Effect of istradefylline on mood disorders in Parkinson's disease

Nagayama, H., Kano, O., Murakami, H., Ono, K., Hamada, M., Toda, T., Sengoku, R., Shimo, Y., & Hattori, N. (2018) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2018.11.005 · Cited by 52 · see citing works

Safety and effectiveness of istradefylline in patients with Parkinson’s disease: interim analysis of a post-marketing surveillance study in Japan

Takahashi, M., Fujita, M., Asai, N., Saki, M., & Mori, A. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1518433 · Cited by 51 · see citing works

The Corticostriatal Adenosine A2A Receptor Controls Maintenance and Retrieval of Spatial Working Memory

Li, Z., Chen, X., Wang, T., Gao, Y., Li, F. Y., Chen, L., Xue, J., He, Y., Li, Y., Guo, W. M., et al. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.07.017 · Cited by 49 · see citing works

How do adenosine A2A receptors regulate motor function?

Mori, A. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.09.025 · Cited by 50 · see citing works

The Impact of Purinergic System Enzymes on Noncommunicable, Neurological, and Degenerative Diseases

Bagatini, M. D., dos Santos, A. A., Cardoso, A. M., Mânica, A., Reschke, C. R., & Carvalho, F. B. (2018) · Journal of Immunology Research · doi:10.1155/2018/4892473 · Cited by 49 · see citing works

Efficacy of istradefylline for gait disorders with freezing of gait in Parkinson’s disease: A single-arm, open-label, prospective, multicenter study

Iijima, M., Orimo, S., Terashi, H., Suzuki, M., Hayashi, A., Shimura, H., Mitoma, H., Kitagawa, K., & Okuma, Y. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1614167 · Cited by 46 · see citing works

Adenosine A2A Receptors Control Glutamatergic Synaptic Plasticity in Fast Spiking Interneurons of the Prefrontal Cortex

Kerkhofs, A., Canas, P. M., Timmerman, A., Heistek, T. S., Real, J. I., Xavier, A. C., Cunha, R. A., Mansvelder, H. D., & Ferreira, S. G. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00133 · Cited by 43 · see citing works

Adenosine A2A receptor involves in neuroinflammation-mediated cognitive decline through activating microglia under acute hypobaric hypoxia

Chen, P.-Z., He, W., Zhu, Z.-R., Guoji, E., Xu, G., Chen, D., & Gao, Y. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.02.038 · Cited by 41 · see citing works

Adenosine A2Areceptors facilitate synaptic NMDA currents in CA1 pyramidal neurons

Mouro, F. M., Rombo, D. M., Dias, R. B., Ribeiro, J. A., & Sebastião, A. M. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14497 · Cited by 38 · see citing works

Purinergic receptors in cognitive disturbances

Illés, P., Ulrich, H., Chen, J., & Tang, Y. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106229 · Cited by 37 · see citing works

Adenosine effects on inhibitory synaptic transmission and excitation–inhibition balance in the rat neocortex

Zhang, P., Bannon, N. M., Ильин, В. Н., Volgushev, M., & Chistiakova, M. (2014) · The Journal of Physiology · doi:10.1113/jphysiol.2014.279901 · Cited by 34 · see citing works

The 1,2,4-Triazolo[4,3-a]pyrazin-3-one as a Versatile Scaffold for the Design of Potent Adenosine Human Receptor Antagonists. Structural Investigations to Target the A2AReceptor Subtype

Falsini, M., Squarcialupi, L., Catarzi, D., Varano, F., Betti, M., Ben, D. D., Marucci, G., Buccioni, M., Volpini, R., Vita, T. D., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00457 · Cited by 35 · see citing works

Decreased synaptic plasticity in the medial prefrontal cortex underlies short-term memory deficits in 6-OHDA-lesioned rats

MATHEUS, F. C., Rial, D., Real, J. I., Lemos, C., Ben, J., Guaita, G. O., Pita, I. R., Sequeira, A., Pereira, F. C., Walz, R., et al. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.12.011 · Cited by 35 · see citing works

Quantifying the inverted U: A meta-analysis of prefrontal dopamine, D1 receptors, and working memory.

Weber, M. A., Conlon, M. M., Stutt, H. R., Wendt, L. H., Eyck, P. T., & Narayanan, N. S. (2022) · Behavioral Neuroscience · doi:10.1037/bne0000512 · Cited by 35 · see citing works

Can adenosine A2A receptor antagonists be used to treat cognitive impairment, depression or excessive sleepiness in Parkinson's disease?

Jenner, P. G., Mori, A., & Kanda, T. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.09.022 · Cited by 33 · see citing works

The Adenosine Neuromodulation System in Schizophrenia

Rial, D., Lara, D. R., & Cunha, R. A. (2014) · International review of neurobiology · doi:10.1016/b978-0-12-801022-8.00016-7 · Cited by 32 · see citing works

Arterial spin labeling versus BOLD in direct challenge and drug-task interaction pharmacological fMRI

Stewart, S. B., Koller, J. M., Campbell, M. C., & BLACK, K. J. (2014) · PeerJ · doi:10.7717/peerj.687 · Cited by 30 · see citing works

Novel therapeutic interventions for combating Parkinson’s disease and prospects of Nose-to-Brain drug delivery

Ahmad, J., Haider, N., Khan, M. A., Md, S., Alhakamy, N. A., Ghoneim, M. M., Alshehri, S., Imam, S. S., Ahmad, M. Z., & Mishra, A. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114849 · Cited by 31 · see citing works

Striatopallidal adenosine A2A receptor modulation of goal-directed behavior: Homeostatic control with cognitive flexibility

Chen, J., Choi, D., & Cunha, R. A. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109421 · Cited by 29 · see citing works

Adenosine A2A receptors modulate the dopamine D2 receptor‐mediated inhibition of synaptic transmission in the mouse prefrontal cortex

Real, J. I., Simões, A. P., Cunha, R. A., Ferreira, S. G., & Rial, D. (2018) · European Journal of Neuroscience · doi:10.1111/ejn.13912 · Cited by 29 · see citing works

Sex-dependent changes in ADHD-like behaviors in juvenile rats following cortical dopamine depletion

Freund, N., MacGillivilray, H. T., Thompson, B. S., Lukkes, J. L., Stanis, J. J., Brenhouse, H. C., & Andersen, S. L. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.05.024 · Cited by 27 · see citing works

Does the functional assessment measure (FAM) extend the functional independence measure (FIM) instrument? A rasch analysis of stroke inpatients.

Linn, R. T., Blair, R., Granger, C. V., Harper, D. W., O'Hara, P. A., & Maciura, E. (1999) · PubMed · Cited by 26 · see citing works

Adenosine A2A Receptors in the Rat Prelimbic Medial Prefrontal Cortex Control Delay-Based Cost-Benefit Decision Making

Leffa, D. T., Pandolfo, P., Gonçalves, N., Machado, N. J., de Souza, C. M., Real, J. I., Silva, A. C., Silva, H. B. L., Köfalvi, A., Cunha, R. A., et al. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00475 · Cited by 25 · see citing works

Catecholamine-Based Treatment in AD Patients: Expectations and Delusions

Stefani, A., Olivola, E., Liguori, C., Hainsworth, A. H., Saviozzi, V., Angileri, G., D’Angelo, V., Galati, S., & Pierantozzi, M. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00067 · Cited by 24 · see citing works

7-Amino-2-phenylpyrazolo[4,3-d]pyrimidine derivatives: Structural investigations at the 5-position to target human A1 and A2A adenosine receptors. Molecular modeling and pharmacological studies

Squarcialupi, L., Colotta, V., Catarzi, D., Varano, F., Betti, M., Varani, K., Vincenzi, F., Borea, P. A., Porta, N., Ciancetta, A., et al. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.07.060 · Cited by 24 · see citing works

Effects of the Adenosine A2A Receptor Antagonist on Cognitive Dysfunction in Parkinson's Disease

Uchida, S., Kadowaki-Horita, T., & Kanda, T. (2014) · International review of neurobiology · doi:10.1016/b978-0-12-801022-8.00008-8 · Cited by 24 · see citing works

An Anti-Parkinson’s Disease Drug via Targeting Adenosine A2A Receptor Enhances Amyloid-β Generation and γ-Secretase Activity

Lü, J., Cui, J., Li, X., Wang, X., Zhou, Y., Yang, W., Chen, M., Zhao, J., & Pei, G. (2016) · PLoS ONE · doi:10.1371/journal.pone.0166415 · Cited by 23 · see citing works

The novel psychoactive substance methoxetamine induces persistent behavioral abnormalities and neurotoxicity in rats

Costa, G., Serra, M., Pintori, N., Casu, M. A., Zanda, M. T., Murtas, D., Luca, M. A. D., Simola, N., & Fattore, L. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.10.031 · Cited by 22 · see citing works

Shared cerebral metabolic pathology in non-transgenic animal models of Alzheimer's and Parkinson's disease

Barilar, J. O., Knezović, A., Perhoč, A. B., Homolak, J., Riederer, P. F., & Šalković‐Petrišić, M. (2020) · Journal of Neural Transmission · doi:10.1007/s00702-020-02152-8 · Cited by 22 · see citing works

Two new adenosine receptor antagonists for the treatment of Parkinson's disease: istradefylline versus tozadenant

Perez‐Lloret, S., & Merello, M. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.903924 · Cited by 21 · see citing works

Influence of dopamine transmission in the medial prefrontal cortex and dorsal striatum on the emission of 50-kHz ultrasonic vocalizations in rats treated with amphetamine: Effects on drug-stimulated and conditioned calls

Costa, G., Serra, M., Marongiu, J., Morelli, M., & Simola, N. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.109797 · Cited by 19 · see citing works

Targeting the adenosine A2A receptor for neuroprotection and cognitive improvement in traumatic brain injury and Parkinson's disease

Zhao, Y., Zhou, Y.-G., & Chen, J.-F. (2023) · Chinese journal of traumatology = Zhonghua chuang shang za zhi · doi:10.1016/j.cjtee.2023.08.003 · Cited by 16 · see citing works

Trends on Novel Targets and Nanotechnology-Based Drug Delivery System in the Treatment of Parkinson's disease: Recent Advancement in Drug Development

Majumdar, M., & Badwaik, H. R. (2024) · Current Drug Targets · doi:10.2174/0113894501312703240826070530 · Cited by 16 · see citing works

Combined Therapy of A1AR Agonists and A2AAR Antagonists in Neuroinflammation

Marucci, G., Ben, D. D., Lambertucci, C., Navia, A. M., Spinaci, A., Volpini, R., & Buccioni, M. (2021) · Molecules · doi:10.3390/molecules26041188 · Cited by 16 · see citing works

Experimental Models of Cognitive Impairment for Use in Parkinson’s Disease Research: The Distance Between Reality and Ideal

Fan, Y., Han, J., Zhao, L., Wu, C., Wu, P., Huang, Z., Hao, X., Ji, Y., Chen, D., & Zhu, M. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.745438 · Cited by 16 · see citing works

Emerging Nondopaminergic Medications for Parkinson’s Disease: Focusing on A2A Receptor Antagonists and GLP1 Receptor Agonists

Shang, P., Baker, M. R., Banks, S. A., Hong, S., & Choi, D. (2021) · Journal of Movement Disorders · doi:10.14802/jmd.21035 · Cited by 16 · see citing works

Modulation of adenosine signaling reverses 3-nitropropionic acid-induced bradykinesia and memory impairment in adult zebrafish

Wiprich, M. T., Altenhofen, S., Gusso, D., Vasques, R. D. R., Zanandrea, R., Kist, L. W., Bogo, M. R., & Bonan, C. D. (2022) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2022.110602 · Cited by 12 · see citing works

Promising biomarkers and therapeutic targets for the management of Parkinson's disease: recent advancements and contemporary research

Khan, M. A., Haider, N., Singh, T., Bandopadhyay, R., Ghoneim, M. M., Alshehri, S., Taha, M., Ahmad, J., & Mishra, A. (2023) · Metabolic Brain Disease · doi:10.1007/s11011-023-01180-z · Cited by 12 · see citing works

The role of glutamate mGlu5 and adenosine A2a receptor interactions in regulating working memory performance and persistent cocaine seeking in rats

Hámor, P. U., Gobin, C. M., & Schwendt, M. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.109979 · Cited by 11 · see citing works

The Anti-Parkinsonian A2A Receptor Antagonist Istradefylline (KW-6002) Attenuates Behavioral Abnormalities, Neuroinflammation, and Neurodegeneration in Cerebral Ischemia: An Adenosinergic Signaling Link Between Stroke and Parkinson’s Disease

Zaki, M. G., Jakova, E., Pordeli, M., Setork, E., Taghibiglou, C., & Cayabyab, F. S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125680 · Cited by 10 · see citing works

Investigation of Photostability of Istradefylline Aqueous Solution

Xu, H., Wang, Y., Wang, H., Zheng, Z., Meng, Z., Xue, M., & Xu, Z. (2020) · ChemistrySelect · doi:10.1002/slct.201904148 · Cited by 8 · see citing works

Therapeutic Approaches to Non-Motor Symptoms of Parkinson's Disease: A Current Update on Preclinical Evidence

Weerasinghe-Mudiyanselage, P. D. E., Kang, S., Kim, J., & Moon, C. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666221005090126 · Cited by 8 · see citing works

Neurotransmitter Systems in Alzheimer’s Disease

Ramı́rez-Expósito, M. J., Cueto‐Ureña, C., & Martı́nez-Martos, J. M. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48030334 · Cited by 7 · see citing works

Contributions of animal models of cognitive disorders to neuropsychopharmacology

Deguil, J., & Bordet, R. (2021) · Therapies · doi:10.1016/j.therap.2021.02.001 · Cited by 7 · see citing works

The Story of Istradefylline—The First Approved A2A Antagonist for the Treatment of Parkinson’s Disease

Mori, A., LeWitt, P. A., & Jenner, P. G. (2015) · Current topics in neurotoxicity · doi:10.1007/978-3-319-20273-0_13 · Cited by 7 · see citing works

The adenosine A2A receptor antagonist/inverse agonist, KW-6356 enhances the anti-parkinsonian activity of L-DOPA with a low risk of dyskinesia in MPTP-treated common marmosets

Ohno, Y., Okita, E., Kawai-Uchida, M., Shoukei, Y., Soshiroda, K., Kanda, T., & Uchida, S. (2023) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2023.05.001 · Cited by 5 · see citing works

Adenosine A2A Receptors: Localization and Function

Simola, N., & Wardas, J. (2015) · Current topics in neurotoxicity · doi:10.1007/978-3-319-20273-0_1 · Cited by 5 · see citing works

Role of adenosine A2A receptors in hot and cold cognition: Effects of single-dose istradefylline in healthy volunteers

Hook, R. W., Isobe, M., Savulich, G., Grant, J. E., Ioannidis, K., Christmas, D. M., Sahakian, B. J., Robbins, T. W., & Chamberlain, S. R. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2023.03.006 · Cited by 4 · see citing works

Adolescent alcohol exposure disrupts episodic-like memory by impairing dopamine synapses in the mouse prelimbic cortex

Seiglie, M. P., & Umemori, H. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110255 · Cited by 3 · see citing works

The Adenosine Receptor: A Homeostatic Neuromodulator for Fine-Tuning Control of Cognition

Chen, J. (2018) · Springer eBooks · doi:10.1007/978-3-319-90808-3_15 · Cited by 2 · see citing works

In silico investigation of the selectivity mechanism of A 1 AR and A 2A AR antagonism

Li, W., Hu, B., Liu, H., Luan, J., Chen, L., Wang, S., Fan, L., & Wang, J. (2022) · New Journal of Chemistry · doi:10.1039/d2nj03536g · Cited by 1 · see citing works

Impact of istradefylline on motor and non-motor symptoms in patients with Parkinson’s disease: Subanalysis of the ISTRA ADJUST PD

Nagayama, H., Kano, O., Sengoku, R., Yanagisawa, N., Yoritaka, A., Suzuki, K., Nishikawa, N., Mukai, Y., Nomura, K., Yoshida, N., et al. (2025) · Clinical Parkinsonism & Related Disorders · doi:10.1016/j.prdoa.2025.100327 · Cited by 1 · see citing works

Istradefylline for Treating Parkinson’s Disease

Kanda, T., & Nomoto, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_361 · Cited by 1 · see citing works

Role of Adenosine in the Basal Ganglia

Morelli, M., Simola, N., Popoli, P., & Carta, A. R. (2016) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-12-802206-1.00012-x

Adenosine A2A Receptor-Mediated Control of Non-Motor Functions in Parkinson’s Disease

Prediger, R. D., MATHEUS, F. C., de Oliveira, P. A., Rial, D., Moretti, M., Souza, A. C. G., Aguiar, A. S., & Cunha, R. A. (2015) · Current topics in neurotoxicity · doi:10.1007/978-3-319-20273-0_10

Adenosinergic Receptor Antagonists: Clinical Experience in Parkinson’s Disease

Pourcher, E., & Hauser, R. A. (2015) · Current topics in neurotoxicity · doi:10.1007/978-3-319-20273-0_14

Istradefylline for Treating Parkinson’s Disease

Kanda, T., & Nomoto, M. (2019) · Springer eBooks · doi:10.1007/978-3-319-56015-1_361-1

Peer Review #1 of "Arterial spin labeling versus BOLD in direct challenge and drug-task interaction pharmacological fMRI (v0.2)"

(2014) · PeerJ · doi:10.7287/peerj.687v0.2/reviews/1

Peer Review #1 of "Arterial spin labeling versus BOLD in direct challenge and drug-task interaction pharmacological fMRI (v0.1)"

(2014) · PeerJ · doi:10.7287/peerj.687v0.1/reviews/1

Peer Review #2 of "Arterial spin labeling versus BOLD in direct challenge and drug-task interaction pharmacological fMRI (v0.1)"

(2014) · PeerJ · doi:10.7287/peerj.687v0.1/reviews/2

Peer Review #2 of "Arterial spin labeling versus BOLD in direct challenge and drug-task interaction pharmacological fMRI (v0.2)"

(2014) · PeerJ · doi:10.7287/peerj.687v0.2/reviews/2

BindingDB Entry 50049297: The 1,2,4-Triazolo[4,3-a]pyrazin-3-one as a Versatile Scaffold for the Design of Potent Adenosine Human Receptor Antagonists. Structural Investigations to Target the A

BindingDB (2019) · UC San Diego · doi:10.7270/q21v5h87

BindingDB Entry 50045282: 7-Amino-2-phenylpyrazolo[4,3-d]pyrimidine derivatives: structural investigations at the 5-position to target human A1 and A(2A) adenosine receptors. Molecular modeling and pharmacological studies.

BindingDB (2016) · UC San Diego · doi:10.7270/q2bg2qnh

Effects of the Adenosine A2A Receptor Antagonist on Cognitive Dysfunction in Parkinson's Disease

Uchida, S., Kadowaki-Horita, T., & Kanda, T. (2014) · International review of neurobiology · doi:10.1016/b978-0-12-801022-8.00008-8 · Cited by 24 · see citing works

An evaluation of istradefylline treatment on Parkinsonian motor and cognitive deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque models

Ko, W. K. D., Camus, S. M. J., Li, Q., Yang, J., McGuire, S., Pioli, E. Y., & Bézard, E. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.07.012 · Cited by 53 · see citing works

Antagonismo do receptor da adenosina A2a : nova perspectiva para o tratamento da doença de Parkinson

Aguiar, L. M. V. (2009) · Americanae (AECID Library)

Adenosine A2a receptor antagonists : a new alternative for parkinson disease treatment

Aguiar, L. M. V. (2009) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)

The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosets

Uchida, S.-I., Soshiroda, K., Okita, E., Kawai-Uchida, M., Mori, A., Jenner, P. G., & Kanda, T. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.11.038 · Cited by 29 · see citing works